{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:07:29Z","timestamp":1794251249291,"version":"4.9.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Medications for alcohol use disorder (MAUD) are highly effective in achieving and maintaining abstinence in patients with alcohol use disorder (AUD). Our aim was to evaluate the effect of MAUD on all-cause mortality in patients with alcohol-associated cirrhosis and active alcohol use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of patients with alcohol-associated cirrhosis and high-risk alcohol use disorder in the Veterans Outcomes and Costs Associated with Liver Disease (VOCAL) database. Propensity score matching for exposure to MAUD (acamprosate or naltrexone) within a year after cirrhosis diagnosis was performed to account for potential confounders, and the association between MAUD and all-cause mortality was subsequently evaluated using Cox regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 9131 patients were included, of whom 886 (9.7%) were exposed to MAUD (naltrexone: 520, acamprosate: 307, both medications: 59). The duration of MAUD exposure was &gt;3 months in 345 patients (39%). The strongest positive predictor of MAUD prescription was an inpatient diagnosis code for AUD, followed by a concurrent diagnosis of depression; the strongest negative predictor was a history of cirrhosis decompensation. After propensity score matching (866 patients in each group) with excellent covariate balance (absolute standardized mean differences &lt;0.1), MAUD exposure was associated with improved survival, with an HR of 0.80 relative to no MAUD exposure (95% CI: 0.67\u20130.97,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.024).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>MAUD are underutilized in patients with alcohol-associated cirrhosis with high-risk alcohol use behavior but are associated with improved survival after adjustment for confounders such as the severity of liver disease, age, and engagement in the healthcare system.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/hc9.0000000000000093","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T15:00:09Z","timestamp":1679929209000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":77,"title":["Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis"],"prefix":"10.1097","volume":"7","author":[{"given":"Anahita","family":"Rabiee","sequence":"first","affiliation":[{"name":"Section of Digestive Diseases, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Mahmud","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Gastroenterology Section, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Falker","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, New Haven, Connecticut, USA"},{"name":"Department of Internal Medicine & Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Garcia-Tsao","sequence":"additional","affiliation":[{"name":"Section of Digestive Diseases, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"VA Connecticut Healthcare System, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Taddei","sequence":"additional","affiliation":[{"name":"Section of Digestive Diseases, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"VA Connecticut Healthcare System, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Gastroenterology Section, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4]]},"reference":[{"key":"R1-20240826","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"key":"R2-20240826","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.29338","article-title":"Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival","volume":"66","author":"Altamirano","year":"2017","journal-title":"Hepatology"},{"key":"R3-20240826","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1053\/j.gastro.2004.09.020","article-title":"Alcohol and hepatocellular carcinoma","volume":"127","author":"Morgan","year":"2004","journal-title":"Gastroenterology"},{"key":"R4-20240826","doi-asserted-by":"crossref","first-page":"k2817","DOI":"10.1136\/bmj.k2817","article-title":"Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study","volume":"362","author":"Tapper","year":"2018","journal-title":"BMJ"},{"key":"R5-20240826","doi-asserted-by":"crossref","first-page":"e2118713","DOI":"10.1001\/jamanetworkopen.2021.18713","article-title":"Trends in liver transplantation for acute alcohol-associated hepatitis during the COVID-19 pandemic in the US","volume":"4","author":"Bittermann","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R6-20240826","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/jamainternmed.2018.6536","article-title":"National trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States","volume":"179","author":"Lee","year":"2019","journal-title":"JAMA Intern Med"},{"key":"R7-20240826","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"R8-20240826","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association Practice Guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","author":"Reus","year":"2018","journal-title":"Am J Psychiatry"},{"key":"R9-20240826","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40263-013-0043-4","article-title":"Management of alcohol dependence in patients with liver disease","volume":"27","author":"Addolorato","year":"2013","journal-title":"CNS Drugs"},{"key":"R10-20240826","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"R11-20240826","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/acps.12905","article-title":"Baclofen for alcohol use disorder-a systematic meta-analysis","volume":"138","author":"Bschor","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"R12-20240826","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/pds.4635","article-title":"Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France","volume":"27","author":"Chaignot","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R13-20240826","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1176\/ps.2010.61.4.392","article-title":"Pharmacotherapy of alcohol use disorders in the Veterans Health Administration","volume":"61","author":"Harris","year":"2010","journal-title":"Psychiatr Serv"},{"key":"R14-20240826","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.31042","article-title":"Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis","volume":"71","author":"Rogal","year":"2020","journal-title":"Hepatology"},{"key":"R15-20240826","doi-asserted-by":"crossref","first-page":"e2213014","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder","volume":"5","author":"Vannier","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R16-20240826","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2020.12.004","article-title":"Cost-effectiveness of alcohol use treatments in patients with alcohol-associated cirrhosis","volume":"74","author":"Avance\u00f1a","year":"2021","journal-title":"J Hepatol"},{"key":"R17-20240826","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/acer.13944","article-title":"Gender disparities in alcohol use disorder treatment among privately insured patients with alcohol-associated cirrhosis","volume":"43","author":"Mellinger","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"key":"R18-20240826","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis","volume":"156","author":"Kaplan","year":"2019","journal-title":"Gastroenterology"},{"key":"R19-20240826","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2007.03572.x","article-title":"The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases: Liver Disease Codes Validation Study","volume":"27","author":"Kramer","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-20240826","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.drugalcdep.2012.05.029","article-title":"Comparative performance of the AUDIT-C in screening for DSM-IV and DSM-5 alcohol use disorders","volume":"126","author":"Dawson","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"R22-20240826","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.cgh.2015.07.010","article-title":"Development and performance of an algorithm to estimate the Child-Turcotte-Pugh Score from a National Electronic Healthcare Database","volume":"13","author":"Kaplan","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R23-20240826","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"R24-20240826","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1053\/j.gastro.2015.07.056","article-title":"Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US Veterans, 2001\u20132013","volume":"149","author":"Beste","year":"2015","journal-title":"Gastroenterology"},{"key":"R25-20240826","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.2105\/AJPH.2015.302836","article-title":"Prevalence, comorbidity, and prognosis of mental health among US Veterans","volume":"105","author":"Trivedi","year":"2015","journal-title":"Am J Public Health"},{"key":"R26-20240826","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1478-7954-4-2","article-title":"Accuracy and completeness of mortality data in the Department of Veterans Affairs","volume":"4","author":"Sohn","year":"2006","journal-title":"Popul Health Metr"},{"key":"R28-20240826","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMct0801733","article-title":"Naltrexone for the management of alcohol dependence","volume":"359","author":"Anton","year":"2008","journal-title":"N Engl J Med"},{"key":"R30-20240826","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1360-0443.2006.01310.x","article-title":"Rates and predictors of relapse after natural and treated remission from alcohol use disorders","volume":"101","author":"Moos","year":"2006","journal-title":"Addiction"},{"key":"R31-20240826","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.drugalcdep.2016.06.027","article-title":"National trends in alcohol pharmacotherapy: findings from an Australian claims database","volume":"166","author":"Morley","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"R32-20240826","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"R33-20240826","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1037\/a0030949","article-title":"Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers","volume":"10","author":"Harris","year":"2013","journal-title":"Psychol Serv"},{"key":"R34-20240826","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11920-011-0222-2","article-title":"Barriers to use of pharmacotherapy for addiction disorders and how to overcome them","volume":"13","author":"Oliva","year":"2011","journal-title":"Curr Psychiatry Rep"},{"key":"R35-20240826","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.amepre.2018.01.004","article-title":"Geographic variation in the supply of selected behavioral health providers","volume":"54","author":"Andrilla","year":"2018","journal-title":"Am J Prev Med"},{"key":"R37-20240826","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.15585\/mmwr.mm6932a1","article-title":"Mental health, substance use, and suicidal ideation during the COVID-19 pandemic\u2014United States, June 24-30, 2020","volume":"69","author":"Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R38-20240826","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/08897077.2016.1189477","article-title":"Medication-assisted treatment for substance use disorders within a national community health center research network","volume":"37","author":"Rieckmann","year":"2016","journal-title":"Subst Abus"},{"key":"R39-20240826","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T11:06:29Z","timestamp":1724670389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hc9.0000000000000093","relation":{},"ISSN":["2471-254X"],"issn-type":[{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"assertion":[{"value":"2023-01-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}